
    
      This is an open-label, non-randomized pharmacokinetic study of two dosage strengths of oral
      Civamide. The study consists of a Screening Period (Days -21 to Day -2), an Admittance
      Period, A 4 Day in-house Treatment Period(Days 1-4))and a follow-up Visit on Day 7.

      Pharmacokinetics will be assessed at specified timepoints relative to dosing on Day 1 during
      the in-house stay. Subjects will be discharged from the research unit following the 72 hr
      blood draw.

      Subjects will return to the research unit on Day 7 for a follow-up safety assessment.
    
  